Product Pipeline
Cantab currently has two active anti-infective therapeutic programmes based on its proprietary peptide-derived antibiotics.
NVB333 is under development for systemic treatment of Gram-positive infections such as MRSA. NVB333 is active against strains resistant to currently-available narrow-spectrum antibiotics such as vancomycin, daptomycin and linezolid.
Cantab's Gram-negative programme concentrates on a peptide-derived series with excellent activity against important pathogens such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii.